

FY 2024 First Quarter Report

July - September 2023



Arkansas Department of Health

BreastCare Quarterly Report July-September Fiscal Year 2024



Funded by the Arkansas Department of Health (ADH) with support from the Centers for Disease Control and Prevention (CDC) and Arkansas Tobacco Excise Tax.

Table 1: Number of Women Enrolled¹, FY 2024

Funding Source	Number of Women Enrolled July-September, FY 2024	Number of Women Enrolled To-Date, FY 2024
Total	3,205	3,205
Federal	2,081	2,081
State	1,124	1,124

Data source: FY 2024 BreastCare Online System Data.

Table 2: BreastCare Funds by Expenditures and Percent Spent on Clinical Services, FY 2024

Month	ylut	August	September	July-September Average	Monthly Average To-Date FY 2024
Total Expenditures	\$326,492	\$352,434	\$314,258	\$331,062	\$331,062
Expenditures on Clinical Services	\$249,683	\$265,746	\$353,397	\$252,609	\$252,609
Percent of Expenditures Spent on Clinical Services	76.5%	75.4%	77.1%	76.3%	76.3%

Data Source: Monthly BreastCare Financial Status Report

¹Unduplicated count of women enrolled in the BreastCare Program during the period.

Table 3: Number and Percent of Screenings Performed, FY 2024

Provider Type	Number of Screenings ¹ , Jul-Sep, FY 2024	Number of Screenings ¹ , To-Date, FY 2024	Percent of Screenings, FY 2024
Health Department Clinic	2,108	2,108	55.8%
Community Health Center	707	707	18.7%
Hospital	750	750	18.8%
Private Provider	214	214	5.7%
Total ¹	3,779	3,779	100%

Data source: FY 2024 BreastCare Online System Data.

Table 4: Number of Screening Tests Performed through BreastCare, FY 2024

Type of Test	Number of Tests Performed Jul-Sep, FY 2024	Number of Tests Performed To-Date, FY 2024	
Clinical Breast Exam ¹	1,258	1,258	
Mammograms ²	899	899	
Pap Tests ³	1,622	1,622	

Data source: FY 2024 BreastCare Online System Data.

¹Number of clinical breast exam performed during the period, clients may receive more than one clinical breast exam.

Table 5: Mammogram Screening History at Enrollment, Women 40 – 64 years old, FY 2024

Last Mammogram	Percent of Enrollees Jul-Sep, FY 2024	Percent of Enrollees To-Date, FY 2024	
Within 2 Years	49.1%	49.1%	
More than 2 Years 24.0%		24.0%	
Never Had Mammogram	26.9%	26.9%	

¹Unique screening tests performed during the period. Screening tests include clinical breast exams, screening mammograms, and Pap tests.

²Number of screening mammograms performed during the period, clients may receive more than one screening mammogram.

³Number of Pap tests performed during the period, clients may receive more than one Pap test.

Table 6: Number of Cancer and Precancer Diagnoses Reported among BreastCare Women, FY 2024

Type of Diagnosis	Number of Diagnoses July-September, FY 2024		Number of Diagnoses To-Date, FY 2024	
	Total (Age < 40)		Total	(Age < 40)
Atypical Hyperplasia and LCIS ¹	4	(0)	4	(0)
Ductal Carcinoma In Situ Breast Cancer ²	3	(1)	3	(1)
Invasive Breast Cancer ³	7	(0)	7	(0)
Cervical Precancer ⁴	28	(16)	28	(16)
Invasive Cervical Cancer ⁵	2	(1)	2	(1)

Data source: FY 2024 BreastCare Online System (BOS) Data

Table 7: BreastCare Funds by Funding Source (Revenue and Expenditures) and Percent Spent on Clinical Services, FY 2021-2024

Funding Source	FY 2021	FY 2022	FY 2023	FY 2024 (Budgeted)
Federal				
Revenue	\$1,700,000	\$1,700,000	\$2,500,000	\$2,365,000
Expenditures	\$1,553,049	\$1,599,714	\$2,421,860	\$2,365,000
State				
Revenue	\$3,224,579	\$3,195,344	\$2,965,580	3,113,563
Expenditures	\$3,217,868	\$3,415,132	\$3,101,755	3,113,563
Percent of Expenditures Spent on Clinical Services	65%	72%	67%	74%

Data Source: BreastCare Monthly Budget Report

¹Unduplicated count of women with a biopsy diagnosis of atypical ductal hyperplasia, atypical lobular hyperplasia, or Lobular Carcinoma in situ reported in BOS during the period.

²Unduplicated count of women with a final diagnosis of Ductal Carcinoma in situ reported in BOS during the period.

³Unduplicated count of women with a final diagnosis of invasive breast cancer reported in BOS during the period.

⁴Unduplicated count of women with a final diagnosis of moderate or severe dysplasia (CIN-2/CIN-3) reported in BOS during this period.

⁵Unduplicated count of women with a final diagnosis of invasive cervical cancer reported in BOS during the period.

Table 8: BreastCare Clinical Services Expenditures by Funding Source, FY 2020-2023

Funding Source	FY 2021	FY 2022	FY 2023	FY 2024 (Budgeted)
Federal Grant	\$1,272,753	\$1,361,448	\$1,858,188	\$1,978,397
State Tobacco Excise Tax	\$1,809,999	\$1,908,096	\$1,817,162	\$2,057,185
Total	\$3,082,752	\$3,269,544	\$3,675350	\$4,035,582
Total Number of Women Served	8,411	9,339	10,132	10,638
Average Cost of Each Woman Served	\$366.51	\$350.10	\$362.75	\$379.36

Data source: BreastCare Budget

¹Clinical Services - Direct service provided to women who enroll in the program. These services consist of screening, diagnostic and case management services as well as salaries for Nurse Practitioners and Public Health Nurses who provide one-on-one services.

Table 9: Clinical Services Provided by BreastCare Funding Sources, FY 2023

Funding Source	Number of Women Enrolled¹ (% of total)	Number of Women Served ^{2,4} (% of total)	Number of Women Screened ^{3,4} (% of total)
Federal	7,177 (62.0%)	5,974 (59.0%)	5,762 (59.3%)
State	4,395 (38.0%)	4,158 (41.0%)	3,957 (40.7%)
Total	11,572 (100%)	10,132 (100%)	9,719 (100%)

Data Source: FY 2023 BreastCare Online System Data

¹Unduplicated count of women enrolled into BreastCare during the period.

²Unduplicated count of women receiving any clinical service through BreastCare during the period. Clinical services are related to breast and cervical cancers including screening and diagnostic procedures.

³Unduplicated count of women who received any screening procedure through BreastCare during the period. Screening procedures include clinical breast exams, mammograms and Pap tests.

⁴Numbers may change based on billing cycles and delays.

Definitions Used in This Report:

Updated: August, 2023

- 1. <u>Women enrolled</u>: Unduplicated count of women enrolled into the ADH BreastCare Program during a specified time period; *Source of report: BreastCare Online System*.
- 2. <u>Women served</u>: Unduplicated count of women receiving <u>any</u> clinical service through BreastCare Program during a specified time period. Clinical services include screening and diagnostic procedures; *Source of report: BreastCare Online System*.
- 3. <u>Women screened</u>: Unduplicated count of women receiving <u>any</u> screening procedure through BreastCare Program during a specified time period. Screening procedures include clinical breast exam, screening mammogram, and Pap test; *Source of report: BreastCare Online System*.
- 4. <u>Screenings by provider type</u>: Unduplicated count of screening procedures through BreastCare Program during a specified time period. Screening procedures include clinical breast exam, conventional mammogram, digital mammogram, conventional Pap test, and liquid-based Pap test; *Source of report: BreastCare Online System*.
- 5. <u>Clinical Breast Exams performed</u>: Number of clinical breast exams provided by BreastCare Program, sometimes more than one for the same client, during a specific time period; *Source of Report: BreastCare Online System*.
- 6. <u>Mammograms performed</u>: Number of screening mammograms provided by BreastCare Program, sometimes more than one for the same client, during a specified time period; Source of Report: BreastCare Online System.
- 7. <u>Pap tests performed</u>: Total number of Pap tests provided by BreastCare Program, sometimes more than one for the same client, during a specified time period; *Source of Report: BreastCare Online System.*
- 8. <u>Atypical hyperplasia diagnosis or LCIS</u>: Unduplicated count of women with a final diagnosis of atypical hyperplasia or Lobular Carcinoma in situ reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*
- 9. <u>Ductal Carcinoma In Situ Breast cancer diagnosis</u>: Unduplicated count of women with a final diagnosis of Ductal Carcinoma in situ reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*.
- 10. <u>Invasive Breast cancer diagnosis</u>: Unduplicated count of women with a final diagnosis of invasive breast cancer reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*.
- 11. <u>Cervical precancer diagnosis</u>: Unduplicated count of women with a final diagnosis of moderate or severe dysplasia (CIN-2 or CIN-3) reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; Source of Report: BreastCare Online System

12. <u>Invasive Cervical cancer diagnosis</u>: Unduplicated count of women with a final diagnosis of invasive cervical cancer reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*.